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Stevia  rebaudiana  (Bertoni)  Bertoni,  Asteraceae,  is  a plant  with  hypoglycemic  and  antihyperlipidemic
properties.  S. rebaudiana  (SrB)  has  become  a lead  candidate  for the  treatment  of the  diabetes  melli-
tus. However,  chronic  administrations  of S.  rebaudiana  are  required  to  cause  the normoglycemic  effect.
Importantly,  nanomaterials  in  general  and  titanium  dioxide  (TiO2)  in  particular  have  become  effective
tools  for  drug  delivery.  In this  work,  we  obtained  TiO2 nanomaterials  with  SrB  at  different  concentra-
tions  (10, 20  and  30 M)  by  sol–gel  method.  After this  nanomaterials  were  characterized  by  Fourier
transform  infrared  spectroscopy  and  transmission  electron  microscopy.  Where  it was  demonstrated,  the
presence  of  the S. rebaudiana  in TiO2 nanomaterials,  which  were  observed  as  hemispherical  agglomerated
particles  of  different  sizes.  The  nanomaterials  were  evaluated  in  male  rats  whose  diabetes  mellitus-
phenotype  was  induced  by alloxan  (200  mg/kg,  i.p.). The  co-administration  of TiO2-SrB  (20  and  30  M)
induced  a signiﬁcant  and  permanent  decrease  in  the  glucose  concentration  since  4 h, until  30  days
post-administration.  Likewise,  the  concentrations  of insulin,  glycosylated  hemoglobin,  cholesterol,  and
triacylglycerides  showed  a  signiﬁcant  recovery  to basal  levels.  The  major  ﬁnding  of the  study  was  that
the TiO2-SrB  (20  and  30 M) has  a  potent  and  prolonged  activity  antidiabetic.  TiO2 can  be considered  like
an  appropriated  vehicle  in the  continuous  freeing  of  active  substances  to treat of  diabetes  mellitus.
© 2015 Sociedade  Brasileira  de  Farmacognosia.  Published  by Elsevier  Editora  Ltda.  All  rights  reserved.ntroduction
Traditional medicine principally derived from plants and cur-
ently represents a therapeutic potential for Diabetes mellitus (DM)
Laitiff et al., 2010; Malviya et al., 2010).
Stevia rebaudiana (Bertoni) Bertoni (SrB), also known as “sweet
erb,” is a shrubby perennial plant belonging to the Asteraceae
amily (Soejarto et al., 1982). SrB sheets containing approximately
–15% stevioside, which have been isolated and characterized by
hemical and spectral studies (Starratt et al., 2002).
SrB has various pharmacological properties including antioxi-
ant activity, antihypertensive, antihyperlipidemic and cardiovas-
ular protector (Chan et al., 1998). Recent studies have shown
hat the SrB stimulates insulin secretion from pancreatic -cells
∗ Corresponding author.
E-mail: alfonso.diaz@correo.buap.mx (A. Díaz).
http://dx.doi.org/10.1016/j.bjp.2015.03.004
102-695X/© 2015 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editoraand cause normolipidemia and normoglycemia in diabetic rats
(Raskovic et al., 2004; Chen et al., 2005). In this sense, SrB provides
evidence of his traditional use in the control of DM.  However, it has
been demonstrated that are required continuous administrations
of SrB to achieve normoglycemic effect (Curry and Roberts, 2008).
One way to address this problem is, to develop a controlled release
system of SrB, in order to reduce the dose and make available SrB
in the target sites and keep its prolonged activity. A variety of sys-
tems have been developed and used, including liposomes, micelles,
dendrimers, and copolymers.
Currently, nanomaterials of titanium dioxide (TiO2) have
attracted attention as delivery potential systems (Barb et al., 2004).
The TiO2 nanomaterials are chemically inert, possess hydrophilic
features and its synthesis isn’t complicated, in addition, these
present high mechanical strength and low toxicity (Son et al., 2007).
Recently the nanomaterials have been implanted in the amygdala of
rats with epilepsy and obtained optimal results, and found that the
porous TiO2 matrix release their contents in a controlled manner
 Ltda. All rights reserved.
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or a period approximately of 500 h (h) (López et al., 2010a,b). Here,
e performed the synthesis of TiO2 nanomaterials from solutions
f titanium n-butoxide and the aqueous extract of SrB concentrate
btained from the dried leaves of the plant. This with the purpose of
sing it as a controlled release system SrB extract. For the above, this
tudy aimed to evaluate the antidiabetic activity of intraperitoneal
njection of TiO2-SrB nanomaterials in a diabetic rat model.
aterials and methods
reparation of SrB-extract
Stevia rebaudiana (Bertoni) Bertoni, Asteraceae, was grown on
ampus grounds of the Benemérita Universidad Autónoma de
uebla (BUAP), México. Dr. Albino Moreno-Rodríguez conﬁrmed
he identiﬁcation, additionally; a sample was deposited in the
otanical garden of the BUAP (ﬁle 21-09/14). Leaves SrB (10 g)
ashed and dried in an Elisa-550 oven for 24 h. Then it pulverized
nd macerated with a solution of ethanol and water (with a ratio of
0:20). The solution obtained from the mashing process is ﬁltered
nd the SrB aqueous extract is placed on a rotary evaporator of the
SEVE-402-2 brand to eliminate to 80% of solvent (water and alco-
ol) under reduced pressure. Thus we obtain the SrB concentrated
xtract to 80 wt.
reparation of TiO2-SrB nanomaterials by sol–gel method
The homogeneous solutions were prepared separately with
ifferent concentrations of the SrB concentrated extract (10, 20
nd 30 M).  Each homogeneous solution containing 150 ml  of
nhydrous 1-butanol (99.8%, Sigma–Aldrich), 10 ml  of deionized
ater and 0.5 g of polyvinylpyrrolidone (with an average molecular
eight of 40,000, Sigma–Aldrich) and the required concentration
f the SrB concentrated extract (10, 20 and 30 M).
For each homogeneous solution was added 21.5 ml  of titanium
-butoxide (97%, Sigma–Aldrich) in a reﬂux system at 70 ◦C with
onstant agitation. The ﬁnal solution with properties of gel was
mmersed in a container with ice for 15 min  at 3 ◦C. The solvent was
emoved on a rotary evaporator at 50 ◦C under vacuum conditions
o ﬁnally obtain the TiO2-SrB nanomaterials (López et al., 2010a,b).
haracterized of TiO2-SrB nanomaterials
nfrared spectroscopy (FTIR)
The TiO2-SrB nanomaterials were mixed with KBr (5 wt %)
nd pressed in transparent wafers. Fourier transform infrared
pectroscopy was recorded using a Perkin-Elmer 1600 spectropho-
ometer (Perkin-Elmer, Shelton, CT) in the 4000–400 cm−1 range,
nd 32 scans were run for each measurement.
canning electron microscopy (SEM)
The particle size was measured using conventional Scanning
lectron microscopy (SEM, Zeiss; Carl Zeiss, Oberkochen, Ger-
any), operated at 100 kV, with entry goniometer at the side and
.4 nm point-to-point resolution, and attached to a CCD camera
MegaVision, Santa Barbara, CA).
nimals
Adult male Long Evans rats (230–250 g) were obtained from Bio-
erio “Claude Bernard” BUAP. Animals were individually housed
n an environment with controlled temperature, humidity, and
ight conditions (12 h light: 12 h dark cycle), with free access to
ood and water. All procedures described in this study were per-
ormed in accordance to the Mexican Law of Animal Treatment
nd Protection Guidelines (NOM-062-ZOO-1999) and the Researchrmacognosia 25 (2015) 145–151
Committee uses of laboratory animals of the BUAP (VIEP-3450-
2013).
Induction of diabetes in rats
The animals were injected with alloxan dissolved in 0.1 M
citrate buffer, pH 4.5 at a dose 200 mg/kg body weight (i.p.). The
alloxan dose was  selected based on various reports (Raskovic et al.,
2004; Szkudelski, 2001). Three day after of the administration of
alloxan, blood samples were taken and blood glucose levels were
determined. Animals that had higher concentrations of glucose
(150 mg/dl) were considered diabetic.
SrB-TiO2 administration protocols
In the experiment a total of forty rats were used, which were
divided in ﬁve groups (n = 8 per group).
Group 1: normal rats treated with TiO2 nanomaterials (vehicle
group)
Group 2: diabetic group treated with TiO2 nanomaterials
Group 3: diabetic rats with TiO2-SrB nanomaterials to 10 M
Group 4: diabetic rats with TiO2-SrB nanomaterials to 20 M
Group 5: diabetic rats with TiO2-SrB nanomaterials to 30 M
The nanomaterials were injected by i.p. The route in all animals
depending of treatment.
Subsequently, both the empty TiO2 nanomaterials (1 g/kg in
sterile water at 37 ◦C) and SrB (10, 20 and 30 M)  (1 g/kg in sterile
water at 37 ◦C) were administered, respectively.
Method for determination of plasma blood glucose level
To evaluate the plasmatic concentration of glucose with respect
at course of time in the animals injected with SrB nanomaterials, the
animals were deprived of the food for 5 h before the determination.
The blood glucose levels were determined at 0, 4, 8 and 24 as well
as at 5, 10, 15 and 30 days after administration of each treatments.
In the experiment the blood glucose level of the animals were esti-
mated by Glucose Oxidase–Peroxidase Enzymatic Method using a
digital glucometer (ACCU-CHEK brand active). Blood from the tail
vein was collected.
Evaluation of the effect of TiO2-SrB nanomaterials on
hyperglycemia and hyperlipidemia induced by alloxan
At 31 days post-injection of TiO2 and TiO2-SrB, the animals of
each experimental group were sacriﬁced by dislocation and by
cardiac puncture. The blood samples were collected to measure
glucose, insulin, glycated hemoglobin, cholesterol and triacylglyc-
erides. Collected samples were centrifuged at 2 × g for 5 min. Serum
determinations of glucose, cholesterol and triacylglycerides were
developed by enzymatic colorimetric assay, following the protocols
respectively labeled according the BioSystem kits and analyzed in a
semi-automated spectrophotometer (Bayer RA-50). Plasma insulin
concentration was  determined by an ELISA immunoassay (Diagnós-
tica Internacional), and antibody-antigen complex was determined
at 415 nm in a Stat fax 2600 plate reader (WinerLab group). The
glycated hemoglobin measuring was carried out by immunoﬂuo-
rescence method, following the protocol according the i-Chroma
kit and it was analyzed in a detector of the same brand.Statistical analysis
The data were expressed as mean ± standard error (SE) for all
experiments. Statistical analysis was developed through of ANOVA
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tig. 1. (A) FTIR spectrum of SrB extract 80 wt%. (B) FTIR spectra of TiO2, SrB/TiO2-10,
rB/TiO2-20 and SrB/TiO2-30 nanomaterials.
nd a conﬁdence level of 95% and, when necessary, the means were
ompared using the Bonferroni test.
esults
haracterization of TiO2-SrB nanomaterials
nfrared Spectroscopy (FTIR)
The FTIR spectrum of SrB extract is presented in Fig. 1A.
he absorption band located at 3383 cm−1, it corresponding to
he stretching vibration mode OH, which identiﬁes the hydroxyl
roups (OH−), of water (H OH), and the alcohol (ethanol, R OH).
he stretching vibration modes  CH CH, of chemical species C H are
ocated to 2988 cm−1. Mode CH of asymmetric stretching vibra-
ion it locates at 2900 cm−1. The vibration band corresponding to
he bending type interactions mode OH of the OH-groups, it is
ssigned of the surface hydroxyl groups of the material, to sol-
ent and the coordinated deformation HOH of Water be located
t 1630 cm−1. The wavenumber to 1425 cm−1 and 1410 cm−1, they
orresponding to the symmetrical stretching vibration COO of
he COO groups and deformation CH3 vibration of modes. Themacognosia 25 (2015) 145–151 147
vibration bands corresponding to the asymmetric stretching vibra-
tion type COO of carboxylate ions are located at 1593 cm−1.
The IR spectrum of TiO2 nanomaterials shows in the Fig. 1B.
The absorption band at 3,339.1 cm−1, correspond to the stretching
vibration mode OH, which identiﬁes the hydroxyl groups (OH−) of
water (H OH), the solvent (butyl alcohol, R OH) and hydroxylation
of gel (Ti OH). The asymmetric stretching vibration modes of CH is
located at 2939.2 cm−1, correspond to the chemical species of the
methyl ( CH3) (Ti O CH3) and ethoxy groups ( Ti OCH2CH3).
The bending mode (OH) localized to 1635.9 cm−1, correspond
to OH groups of water, which are present on the surface of TiO2
nanomaterial. They are mainly associated with the humidity of
the nanomaterial, the solvent and the coordinated deformation
mode of water. In the range (from ∼1400 cm−1 to ∼1300 cm−1)
of electromagnetic radiation, are localized the bending vibration of
symmetrical type of the COO− groups, the vibration asymmetric
deformation of the CH groups and the vibration mode of the defor-
mation scissor of the CH3 of the CH3 groups. In the near infrared
region, the vibration modes Ti–O type bending of the metal-oxygen
interaction, they localized at 745.3 cm−1, to 640.2 cm−1 and to
498.8 cm−1. The TiO2 nanomaterials doped with 20 M and 30 M
of the extract SrB, present similar stretching vibration modes: (OH)
and (CH) and bending vibration modes: (OH), ( HOH), (COO),
(CH), (CH3), (CC), (CO) and (Ti–O), as than those observed in the
TiO2 nanomaterial undoped.
The decrease in intensity of the absorption bands, mainly of OH−
vibration modes corresponding to the humidity (at 1635.9 cm−1)
of SRB-TiO2 with 10, 20 and 30 M nanomaterials, may  be due
to the interaction to SrB aqueous extract with the surface of TiO2
nanoreservoir, as shown in scheme of Fig. 2. It is also important
to note that under these experimental conditions is impossible
to talk about the formation of polymorphs of TiO2 relative to the
concentration of the aqueous extract of SrB.
Scanning electron microscopy (SEM)
The Fig. 3A, show the SEM studies of TiO2 nanomaterial with a
traced area to 100,000 magniﬁcations. The texture of the TiO2 has
shown the form of agglomerated particles with an average particle
diameter of 100 nm.  The micrograph of TiO2 nanomaterial with SrB-
10 M;  present in a swept area to 100,000×. The micrograph of the
TiO2-SrB-10 M nanomaterial present in a swept area of 100,000
magniﬁcations, formless particles with an average area of 70 nm
Fig. 3B, show the micrograph of the nanomaterial of TiO2 with
20 l of SrB (SrB-TiO2-20 l), which presented a swept area to
100,000 magniﬁcations, it showed hemispherical type particle with
an average area of 60 nm.  Similarly, the Fig. 3C show the micrograph
of SrB/TiO2-30 nanomaterial with an average spherical particles
size of 4 nm that are located within the matrix of TiO2. In Fig. 3D,
the increasing in the concentration of the aqueous extract of SrB
in TiO2 nanomaterials, we  note that decreases the average particle
size of nanomaterials of 100 nm (for TiO2) to 4 nm (for SrB-Ti2-30 l
and we  concluded that the molecules of the aqueous extract of SrB
were present in the mesh of TiO2.
Effect of TiO2-SrB nanomaterials treatment about hyperglycemia
induced by alloxan
The results of body weight and blood glucose measurements
are shown in Fig. 4A. As expected in the course of 30 days, the body
weights were decreased in the diabetic group treated with TiO2
but not in the normal rats treated with TiO2. In hyperglycemic ani-
mals treated with nanomaterials with TiO2-SrB the body weight
was recovered of concentration-dependent manner. The animals
treated with the nanomaterials TiO2-SrB at 20 and 30 M showed
a similar weight to the vehicle group during the 4 weeks that devel-
oped in the experiment.
148 A. Langle et al. / Revista Brasileira de Farmacognosia 25 (2015) 145–151
Tiδ+ Ti δ+ Ti δ+ Ti δ+ Ti δ+ Ti δ+ Ti δ+Oδ– Oδ–
Stevioside
Steviol
CH 3
H 3C H3 C
CH 3
CH
3
CH
3
HO
O
OH
HO
HO
HO
HO
HO
H
O
H
OO
O
OO
O
O
O
OH
OH
OH O
HStevioside
Oδ– Oδ–
OH–OH–
–HO
–HO
TiO2
OH–
CH2 H
δ+ δ+ δ+ δ+δ– δ– δ–
CH2CH2
H
H
H HO
O
O
Oδ– Oδ–
 with
o
(
a
l
c
s
3
3
S
w
a
cFig. 2. Scheme of interaction to SrB
In treated rats with alloxan the blood glucose levels at 4, 8
r 24 h, increased (160–180 mg/dl), respect to the vehicle group
80.43 mg/dl) (Fig. 4B). Treatment with TiO2-SrB nanomaterials in
lloxan-treated animals showed a progressive decrease in glucose
evels at 4, 8 and 24 h after administration, which, when it was
ompared with the alloxan + TiO2 treated group, was  observed a
igniﬁcant difference in the animals treated with TiO2-SrB 20 and
0 M (Fig. 4B). (One way ANOVA, Bonferroni post-test, p < 0.05).
Moreover, comparing the glucose concentration at 5, 10, 15 and
0 days in the hyperglycemic rats after administration of TiO2-
rB, was observed, a signiﬁcant decrease in the treated animals
ith TiO2-SrB nanomaterials at 20 and 30 M with respect to the
lloxan + TiO2 group (Fig. 4 C). In this regard, the decrease of glu-
ose levels was observed during 30 days after administration of
Fig. 3. (A) Micrograph of TiO2. (B) SrB/TiO2-10. (C) Sr the surface of TiO2 nanomaterials.
TiO2-SrB at a concentration of 20–30 M (one-way ANOVA, Bon-
ferroni post-test, p < 0.05).
Laboratory studies, developed 31 days after administration of
treatments, show a signiﬁcant increase in the concentration of glu-
cose (86%) of the hyperglycemic group + TiO2, compared to the
normal rats treated with TiO2 (Fig. 5A and B). Consequently, the
concentration of glycosylated hemoglobin in the alloxan + TiO2
group, was higher (38%) compared to the normal rats + TiO2 (Fig. 5C)
(one-way ANOVA, post-Bonferroni test, p < 0.05).
Moreover, the animals of groups of alloxan + TiO2-SrB 20 and
30 M,  had a lower concentration of glucose (20% and 56%) and
glycated hemoglobin (25% and 41%) compared to the alloxan + TiO2
group (Fig. 5A and C). Also, groups with alloxan + TiO2-SrB 20
and 30 M showed a higher insulin concentration compared to
B/TiO2-20, and (D) SrB/TiO2-30 nanomaterials.
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Fig. 4. Effect of administration of TiO2-SrB nanomaterials on the weight and the
time course of the glycemic levels in treated rats with alloxan. The animals were
weighed every week for 4 weeks (A). The blood glucose levels were determined at
0,  4, 8 and 24 h (B), as well as 5, 10, 15 and 30 days (C) after administration of the
nano-TiO2 SrB (10, 20 and 30 M)  in diabetic rats (alloxan, 200 mg/kg). The vehicle
group were administered with the vehicle, and with empty nanomaterials (Vehicle
a
d
g
a
t
w
ﬁ
h
c
i
T
i
i
Vehicle
***
##
###
[gl
uc
os
e] 
mg
/cl
200A
150
100
50
0
Alloxan
+ TiO2
Alloxan
+ TiO2
SrB (10μM)
Alloxan
+ TiO2
SrB (20μM)
Alloxan
+ TiO2
SrB (30μM)
Vehicle Alloxan
+ TiO2
Alloxan
+ TiO2
SrB (10μM)
Alloxan
+ TiO2
SrB (20μM)
Alloxan
+ TiO2
SrB (30μM)
Vehicle Alloxan
+ TiO2
Alloxan
+ TiO2
SrB (10μM)
Alloxan
+ TiO2
SrB (20μM)
Alloxan
+ TiO2
SrB (30μM)
[In
su
lin
e] 
mg
/cl
40B
30
20
10
0
%
 G
lyc
at
ed
 H
b 
(H
bA
1c
)
10C
8
6
2
4
0
***
##
##
***
#
##
Fig. 5. Effect of administration of TiO2-SrB nanomaterials on glucose, insulin and
glycosylated hemoglobin in administered rats with alloxan. Quantiﬁcation was per-
formed in plasma at 31 days after administration of TiO2-SRB (10, 20 and 30 M) or
TiO2 in treated rats with alloxan (200 mg/kg) or vehicle. The graph (A) glucose con-
centration (mg/ml) in plasma and shown in graphs (B) and (C) insulin concentration
(mU/ml), and the percentage of glycosylated hemoglobin, respectively are shown.nd alloxan + TiO2) under the same experimental conditions (n = 8 per group). The
ata show the average weight (g) and glucose concentration (mg/dl) ± SE of each
roup respectively. (One-way ANOVA, Bonferroni post-test, ***p < 0.001: Vehicle vs
lloxan + TiO2; # #p < 0.01 and ###p < 0.001: alloxan + TiO2-SrB vs alloxan + TiO2).
he group with alloxan + TiO2 (80% and 100%) (Fig. 5B). (One
ay ANOVA, Bonferroni post-test, p <0.05). This showed for the
rst time, that nanomaterials TiO2-SrB (20 and 30 M) reversed
yperglycemic effect induced by alloxan, due to the biochemi-
al parameters measured (glucose, glycosylated hemoglobin and
nsulin) are statistically similar to the vehicle group + TiO2.
iO2-SrB nanomaterials treatment effect on hyperlipidemic effects
nduced by alloxan
The results show that the diabetic group treated with TiO2
ncreased the cholesterol and triacylglycerides levels respect toThe data show the mean ± SE of each group respectively. (One-way ANOVA, Bon-
ferroni post-test, ***p < 0.001: Vehicle vs alloxan + TiO2 and ##p < 0.01, ###p < 0.001:
alloxan + TiO2-SrB vs alloxan + TiO2).
normal rats treated with TiO2 (227% and 185%, respectively) (Fig. 6).
Moreover the treatment with TiO2-SrB nanomaterials to 20 or
30 M in diabetic rats decreased the cholesterol (62 and 64%,
respectively) and triacylglycerides levels (59 and 63%, respectively)
respect to diabetic rats with TiO2 (Fig. 6A and B). (One way  ANOVA,
Bonferroni post-test, p < 0.05). Treated animals with TiO2-SrB nano-
materials to 10 M did not modify the biochemical parameters
evaluated.
Discussion
In the present study, we  synthesize the TiO2-SrB nanomateri-
als by the sol–gel method, which were characterized by FTIR and
SEM, showing the interaction of Stevia rebaudiana (Bertoni) Bertoni,
Asteraceae, nanomaterials with TiO2, as agglomerates of differ-
ent sizes. Subsequently, we  investigate the antidiabetic activity of
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iO2-SrB nanomaterials in diabetic rat model induced with alloxan,
hich is a toxic hepato-pancreatic agent, to generate a similar
etabolic changes to the DM.  The alloxan is employed as an exper-
mental diabetogenic to evaluate the effectiveness of new drugs
ith hypoglycemic properties (Szkudelski, 2001).
Glycemia and lipemia evaluations, determines the degree of
etabolic damage that exists in experimental animals. This study
hows that the treatment with TiO2 alone have no effect on glucose
nd lipids values, while TiO2-SrB at 20 or 30 M caused a hypo-
lycemic and antihyperlipidemic effect in diabetic rats induced
ith alloxan, which is a toxic glucose analog, which selectively
estroys insulin-producing beta cells in the pancreas when is
dministered to rodents (Jeppesen et al., 2000), and causes that
ecreted insulin are insufﬁcient to regulate blood glucose, there-
ore in this study the rats exhibited continuous hyperglycemia. This
odel produces a decrease in the insulin levels in the animals, simi-
ar to the reported in several studies. When the rats are treated with
iO2-SrB to 20 or 30 M produce a hypoglycemic effect from 4 h to
1 days after the treatment. These results reveal the importance
f TiO2 nanomaterials as continuous and sustained release drugs
elivery system into the bloodstream.
According to Jeppesen et al. (2000) the SrB exerts a hypo-
lycemic action which is analogous to sulfonylureas, because it
locks K+ channels in pancreatic -cells remaining, depolarized the
embrane and promotes channel opening of voltage-dependent
a+2. Wherein the increase of intracellular Ca+2 is crucial to
nduce insulin secretion from pancreatic -cells and thus cause
he decrease of blood sugar, reaching normal values biologically
Raskovic et al., 2004).
According our results it appears that the treatment with SrB
nto TiO2 nanomaterials on diabetic rats stimulate of remainingrmacognosia 25 (2015) 145–151
-pancreatic cells and induce the insulin secretion constantly. This
insulin promotes the decrease of glucose and glycated hemoglobin
levels in the plasma of the diabetic rats (Park and Cha, 2010).
It is noteworthy that interaction, SrB, with nanomaterials TiO2
decreases progressively, once they are in the aqueous medium,
which provides the blood stream, therefore, the SrB is released and
distributed peripherally to reaching the sites of action and exercise
the respective pharmacological effects. According as suggested by
some work with nanomaterials of TiO2 (López et al., 2010a,b, 2015).
However, it is necessary to demonstrate this process in the future.
In DM,  high lipid levels are present and play an important
toxic role. The present study show high lipid levels in diabetic rats
induced with alloxan but the treatment with nanomaterials of TiO2-
SrB normalize the proﬁle lipids demonstrating the hypolipidemic
effect of SrB. However, the molecular mechanism to regulating
glucose or lipids of the SrB are unknown. At the moment, stud-
ies indicate that SrB has antioxidant and antiapoptotic effects
(Shivanna et al., 2013), which probably helps to enhance the SrB
therapeutic effect. According to Misra et al. (2011) suggest that Ste-
via extract produced good antidiabetic effects together with lesser
loss in body weight and propose that can be used in the prepa-
ration of cough syrups and cold beverages for diabetes patients
(Himanshu et al., 2011).
For above expose, this study describes for the ﬁrst times that is
necessary the delivery system like TiO2 nanomaterials to release
SrB and generate regulation on hyperglycemia and hyperlipi-
demia in diabetic rats induced with alloxan. Our results open a
new opportunity for the treatment of the DM;  however more
studies are needed to better understand the potential use of TiO2-
nanomaterials and SrB in metabolic diseases.
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